IFIH1 and clinically amyopathic dermatomyositis: Before that time, the anti-MDA5+ DM was classified by dermatologists as clinically-amyopathic dermatomyositis (CADM) (7), but according to the latest Dermatomyositis Classification it has been recently termed MDA5+ DM (8, 10).